遗传性与散发性微卫星不稳定/错配修复缺陷转移性结直肠癌的临床与分子特征
该研究回顾性分析了6家法国医院129例MSI/dMMR转移性结直肠癌患者,其中63%为Lynch样、37%为散发性。系统检测MMR、BRAF突变和MLH1甲基化可避免22%的MLH1/PMS2缺失病例被误分类。Lynch样与散发性患者自然史不同,但一线化疗无进展生存期相似。
要点
- 129例MSI/dMMR mCRC中,Lynch样占63%,散发性占37%。
- 基于病历的算法可误分类22%的MLH1/PMS2缺失mCRC。
- Lynch样患者肝转移和转移灶切除更常见,转移灶切除后无病生存更优(HR 0.28)。
核心结论
- Lynch样与散发性MSI/dMMR mCRC呈现不同的自然病史。
- 为区分Lynch样与散发性MSI/dMMR mCRC,应强制进行MMR、BRAF突变和MLH1甲基化检测。
研究设计与样本
- 回顾性研究,在6家法国医院识别MSI/dMMR mCRC患者,共129例。
- 对肿瘤样本进行MSI、dMMR、RAS/RAF突变和MLH1甲基化筛查。
- 散发病例分子定义为MLH1/PMS2表达缺失且伴BRAFV600E和/或MLH1高甲基化、无MMR胚系突变。
主要发现
- 129例中81例(63%)为Lynch样,48例(37%)为散发性。
- 基于当地病历记录的算法(年龄、Amsterdam II标准、当地检测的BRAF和MMR状态)会误分类22%的MLH1/PMS2阴性mCRC。
- 单因素分析中与总生存更好相关的因素:年龄(P < 0.0001)、转移灶切除(P = 0.001)、Lynch样mCRC(P = 0.01),BRAFV600E不相关。
- 多因素分析中与总生存相关的因素:年龄(HR = 3.19,P = 0.01)和转移灶切除(HR = 4.2,P = 0.001),Lynch状态不相关。
- Lynch样患者肝受累和转移灶切除更频繁,转移灶切除后无病生存更优(HR = 0.28,P = 0.01)。
关键数值与推荐
- 散发病例分子定义:MLH1/PMS2表达缺失伴BRAFV600E和/或MLH1高甲基化,且无MMR胚系突变。
- 基于病历的算法误分类率:22%的MLH1/PMS2阴性mCRC。
- 多因素分析中年龄HR = 3.19(P = 0.01),转移灶切除HR = 4.2(P = 0.001)。
- Lynch样患者转移灶切除后无病生存HR = 0.28(P = 0.01)。
- 一线化疗中位无进展生存期:4.2个月和4.2个月(P = 0.44)。
临床怎么用
- 对MSI/dMMR mCRC应系统检测MMR、BRAF突变和MLH1甲基化以区分Lynch样与散发性。
- 区分Lynch样与散发性有助于判断自然病史,并可能指导免疫检查点抑制剂疗效差异的探索。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR) cancer metastatic colorectal cancer (mCRC) exhibit poor prognosis. We aimed to evaluate the relevance of distinguishing sporadic from Lynch syndrome (LS)-like mCRCs. PATIENTS AND METHODS: MSI/dMMR mCRC patients were retrospectively identified in six French hospitals. Tumour samples were screened for MSI, dMMR, RAS/RAF mutations and MLH1 methylation. Sporadic cases were molecularly defined as those displaying MLH1/PMS2 loss of expression with BRAFV600E and/or MLH1 hypermethylation and no MMR germline mutation. RESULTS: Among 129 MSI/dMMR mCRC patients, 81 (63%) were LS-like and 48 (37%) had sporadic tumours; 22% of MLH1/PMS2-negative mCRCs would have been misclassified using an algorithm based on local medical records (age, Amsterdam II criteria, BRAF and MMR statuses when locally tested), compared to a systematical assessment of MMR, BRAF and MLH1 methylation statuses. In univariate analysis, parameters associated with better overall survival were age (P < 0.0001), metastatic resection (P = 0.001) and LS-like mCRC (P = 0.01), but not BRAFV600E. In multivariate analysis, age (hazard ratio (HR) = 3.19, P = 0.01) and metastatic resection (HR = 4.2, P = 0.001) were associated with overall survival, but not LS. LS-like patients were associated with more frequent liver involvement, metastatic resection and better disease-free survival after metastasectomy (HR = 0.28, P = 0.01). Median progression-free survival of first-line chemotherapy was similar between the two groups (4.2 and 4.2 months; P = 0.44). CONCLUSIONS: LS-like and sporadic MSI/dMMR mCRCs display distinct natural histories. MMR, BRAF mutation and MLH1 methylation testing should be mandatory to differentiate LS-like and sporadic MSI/dMMR mCRC, to determine in particular whether immune checkpoint inhibitors efficacy differs in these two populations.
引用
- Cohen R, Buhard O, Cervera P, et al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Eur J Cancer. 2017. PMID: 29055842. doi:10.1016/j.ejca.2017.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。